BackTHC Therapeutics Overview

THC Therapeutics EBIT

Track THC Therapeutics's EBIT ($-490K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$122.96K
↑ 8.25% YoY

As of Apr 30, 2024

Annual EBIT (TTM)

-$485.23K
↓ 1166.32% YoY

Trailing 12 months ending Apr 30, 2024

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

THC Therapeutics (THCT) FAQ

As of the most recent data (April 2024), THCT shows a EBIT of $-490K. That compares with $46K in the prior-year period — down 1166.3% year over year. That is below the sector sector average of $2.4T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, THCT's EBIT is now $-490K (was $46K) — a 1166.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether THC Therapeutics is outperforming or lagging.

The its sector sector average EBIT is about $2.4T. THC Therapeutics is at $-490K, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how THCT stacks up against individual peers as well.

Tracking THCT's ebit over time shows whether THC Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-490K That compares with $46K in the prior-year period — down 1166.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has THC Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-490K) with ownership activity and broader fundamentals.